Application of proprotein convertase subtilisin/kexin type 9 inhibitor, evolocumab, in patients with severe hypertriglyceridemia.
10.1097/CM9.0000000000001896
- Author:
Yanren PENG
1
;
Danxia GUO
;
Sijie JIANG
;
Hua ZHENG
Author Information
1. Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China.
- Publication Type:Letter
- MeSH:
Antibodies, Monoclonal, Humanized/therapeutic use*;
Humans;
Hyperlipidemias;
Hypertriglyceridemia/drug therapy*;
Proprotein Convertases;
Subtilisins
- From:
Chinese Medical Journal
2022;135(6):730-731
- CountryChina
- Language:English
